VRTX
Vertex Pharmaceuticals Inc (VRTX)
Healthcare • NASDAQ • $429.82+1.13%
- Symbol
- VRTX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $429.82
- Daily Change
- +1.13%
- Market Cap
- $109.09B
- Trailing P/E
- 25.51
- Forward P/E
- 19.91
- 52W High
- $507.92
- 52W Low
- $362.50
- Analyst Target
- $549.50
- Dividend Yield
- N/A
- Beta
- 0.30
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment …
Company websiteResearch VRTX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.